Immunotherapy · 2021
Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Bao-Jiang, Gao Song, Zhu Xu, Guo Jian-Hai, Kou Fu-Xin, Liu Shao-Xing, Zhang Xin, Wang Xiao-Dong, Cao Guang, Chen Hui, Liu Peng, Xu Hai-Feng, Gao Qin-Zong, Yang Ren-Jie
Аннотация
Aim: We investigated the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TKIs) for advanced hepatocellular carcinoma (HCC). Method: This retrospective study included HCC patients treated with HAIC, TKIs and anti-PD-1 antibodies between May 2019 and November 2020 in our hospital. Primary end points were progression-free survival and safety. Results: Twenty-seven advanced HCC patients were analyzed. The median follow-up was 12.9 months (range: 4.0-24.0 months) and the median progression-free survival was 10.6 months. The objective response rate and disease control rate were 63.0 and 92.6%, respectively. No treatment-related deaths occurred. Conclusion: In patients with advanced HCC, treatment with HAIC, anti-PD-1 antibodies and oral TKIs was effective and safe.
Предметные рубрики MeSH
Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularFemaleHepatic ArteryHumansImmune Checkpoint InhibitorsImmunotherapyInfusions, Intra-ArterialLiver NeoplasmsMaleMiddle AgedNeoplasm ProteinsProgrammed Cell Death 1 ReceptorProgression-Free SurvivalProtein Kinase InhibitorsSurvival Rate